Intrauterine Devices Market Size & Growth Forecast 2027–2036, By Segments (Type, Distribution Channel), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Intrauterine Devices Market size stood at USD 6.9 billion in 2026 and is predicted to grow at a 3.52% CAGR from 2027 to 2036, crossing USD 9.75 billion by 2036. The industry revenue for 2027 is estimated at USD 7.1 billion.
Get more details on this report
Request Free Sample ReportIntrauterine Devices Market Intelligence Snapshot
Regional Market Dynamics
- North America leads due to established reproductive healthcare services, broad access to trained providers, and strong adoption of long-acting reversible contraception through clinical care settings.
- Asia Pacific is projected to expand at a 4.33% CAGR, driven by improving women's healthcare access, wider contraceptive adoption, and expanding provider networks supporting family planning services.
Segment Momentum
- Hormonal IUD held a 70.07% share in 2026, supported by widespread clinical familiarity and strong demand for reliable, long-acting, reversible contraception requiring minimal ongoing patient involvement.
- Gynecology clinics are growing fastest because they provide specialized contraceptive counseling, insertion, and follow-up services, offering streamlined access that aligns well with routine IUD care and patient management.
Market Expansion Drivers
- Government family planning initiatives increasing adoption of long-acting contraceptive solutions.
- Rising awareness and education programs improving acceptance of intrauterine contraceptive devices.
- Development of next-generation hormone-free IUDs expanding demand for advanced contraceptive options.
Leading Market Participants
- Prominent players in the intrauterine devices market include Bayer AG (Germany), CooperSurgical Inc. (United States), Pregna International Limited (India), EUROGINE, S.L. (Spain), OCON Medical Ltd. (Israel), Mona Lisa N.V. (Belgium), SMB Corporation of India (India), AbbVie Inc. (United States), DKT International (United States), Prosan International BV (Netherlands).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 6.9 billion
- 2027 Estimated Market Size: USD 7.1 billion.
- Projected Market Size: USD 9.75 billion by 2036
- Growth Forecast: 3.52% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Hormonal IUD (Type) | Hospital (Distribution Channel)
- Emerging Opportunity Segment: Hormonal IUD (Type) | Gynecology Clinics (Distribution Channel)
Market Growth Drivers and Industry Trends
Government family planning initiatives increasing adoption of long-acting contraceptive solutions
Public-sector family planning programs are strengthening intrauterine devices market growth by improving access to long-acting contraceptive methods through awareness campaigns, healthcare services, and reproductive health initiatives. Governments and public health systems can encourage the use of long-acting options by integrating contraceptive counseling and device provision into maternal, reproductive, and primary healthcare services, particularly in regions where reducing unintended pregnancies is a policy priority. Greater availability through public facilities and trained healthcare professionals can also lower practical barriers to adoption, while the long-duration nature of IUDs makes them an attractive option for individuals seeking reliable contraception without the need for frequent administration.
Rising awareness and education programs improving acceptance of intrauterine contraceptive devices
Improved patient education is supporting intrauterine devices market demand by addressing misconceptions surrounding insertion, effectiveness, side effects, and long-term use. Awareness initiatives delivered through healthcare providers, community programs, educational materials, and reproductive health counseling can give individuals clearer information for evaluating different contraceptive choices and understanding the suitability of IUDs for their circumstances. As accurate information becomes more accessible, greater familiarity with the procedure and device characteristics can reduce hesitation among potential users, while informed counseling enables healthcare professionals to match contraceptive options with individual preferences and reproductive goals.
Development of next-generation hormone-free IUDs expanding demand for advanced contraceptive options
Technological development in hormone-free intrauterine contraception is creating additional opportunities within the intrauterine devices market by addressing demand from users who prefer to avoid hormonal contraceptive methods. Newer device concepts can focus on improving contraceptive performance, user comfort, insertion characteristics, and duration of use while maintaining a non-hormonal approach. This innovation expands the range of options available to individuals who may have concerns about hormonal exposure or prefer a hormone-free method, while continued refinement of device design can support broader acceptance among patients and healthcare professionals.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Government family planning initiatives increasing adoption of long-acting contraceptive solutions | 1.80% | High | Asia Pacific, Africa, Latin America | High | Near Term |
| Rising awareness and education programs improving acceptance of intrauterine contraceptive devices | 1.50% | Moderate | Asia Pacific, Europe | High | Mid Term |
| Development of next-generation hormone-free IUDs expanding demand for advanced contraceptive options | 1.30% | High | North America, Europe | Emerging | Mid Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America held the largest share of the intrauterine devices market in 2026, supported by established reproductive healthcare infrastructure, broad access to contraceptive services, and increasing awareness of long-acting reversible contraception. Healthcare providers increasingly recognize intrauterine devices as effective options for patients seeking reliable, low-maintenance contraception, supporting their integration into routine family-planning services. Continued attention to reproductive health education, patient counseling, and access to modern contraceptive methods is further reinforcing regional demand.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is experiencing the fastest growth in the intrauterine devices market as healthcare systems expand access to family-planning services and awareness of long-acting contraception improves. Rising healthcare investment, broader availability of reproductive health services, and initiatives aimed at improving maternal and reproductive care are creating new opportunities for adoption. Increasing urbanization and greater consumer awareness of contraceptive choices are also supporting demand, particularly as healthcare delivery becomes more accessible across developing markets.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Care IntegrationGermany prioritizes intrauterine device adoption through standardized gynecological care and evidence-based contraceptive practices. Healthcare providers in Germany continue integrating modern IUD options into preventive women's health services with a focus on long-term patient outcomes.
France 🇫🇷
Reproductive Care AccessibilityFrance supports intrauterine device utilization through comprehensive reproductive healthcare services and preventive care programs. Healthcare professionals in France continue encouraging informed contraceptive choices while expanding access to long-acting reversible contraceptive solutions.
Italy 🇮🇹
Gynecological Practice SupportItaly is advancing the intrauterine devices market by strengthening women's healthcare services and improving clinical adoption of long-term contraception. Italian healthcare providers emphasize patient consultation and reliable contraceptive solutions within routine gynecological practice.
Japan 🇯🇵
Personalized Contraceptive CareJapan is gradually expanding the use of intrauterine devices by improving physician awareness and individualized contraceptive counseling. Medical providers in Japan are focusing on patient education and appropriate device selection for long-term reproductive health management.
South Korea 🇰🇷
Preventive Women's HealthcareSouth Korea is strengthening the intrauterine devices market through broader reproductive health awareness and expanding access to modern contraceptive methods. Healthcare institutions in South Korea continue promoting clinician training and patient-centered family planning services.
United States 🇺🇸
Women's Health InnovationThe U.S. intrauterine devices market emphasizes expanding access to long-acting reversible contraception through advanced product options and broader provider adoption. Healthcare organizations in the U.S. continue supporting patient education and streamlined reproductive healthcare services.
Segment Leadership and Growth Trends
Intrauterine Devices Market Share (%), by Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType Segment Analysis: Hormonal IUD (Largest & Fastest-Growing Segment)
The hormonal IUD segment dominated the intrauterine devices market, holding 70.07% of the market share in 2026, while also representing the fastest-growing type. Its strong position is supported by the combination of long-term contraceptive effectiveness, convenience, and localized hormone delivery, which can also provide benefits such as reduced menstrual bleeding for suitable users. Growing awareness of long-acting reversible contraception and greater preference for low-maintenance birth control options continue to support adoption.
Distribution Channel Segment Analysis: Hospital (Largest Segment) vs Gynecology Clinics (Fastest-Growing Segment)
The hospital segment accounted for the largest share of 57.16% in 2026, reflecting the important role of hospital-based reproductive healthcare services in counseling, device selection, insertion, and follow-up care. Hospitals offer access to specialized clinical expertise and comprehensive gynecological services, supporting their continued relevance for patients seeking professionally administered contraceptive procedures.
Gynecology clinics are the fastest-growing distribution channel as patients increasingly seek specialized, accessible, and more personalized reproductive health services. Dedicated clinics can provide focused contraceptive counseling, streamlined insertion procedures, and follow-up care, while growing awareness of long-acting contraceptive options is supporting greater utilization through these settings.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Hormonal IUD, Copper IUD | Hormonal IUD | Hormonal IUD |
| Distribution Channel | Hospital, Gynecology Clinics, Community Health Care Centers, Others | Hospital | Gynecology Clinics |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Leading companies in the intrauterine devices market:
1. Bayer AG (Germany)
2. CooperSurgical Inc. (United States)
3. Pregna International Limited (India)
4. EUROGINE S.L. (Spain)
5. OCON Medical Ltd. (Israel)
6. Mona Lisa N.V. (Belgium)
7. SMB Corporation of India (India)
8. AbbVie Inc. (United States)
9. DKT International (United States)
10. Prosan International BV (Netherlands)
The intrauterine devices market is advancing with improvements in contraceptive design and long-term effectiveness. Continuous innovation is enhancing safety, comfort, and ease of use. New product introductions are addressing diverse reproductive health needs across populations. The intrauterine devices market is growing with increased adoption of reliable and minimally invasive contraceptive solutions.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Bayer AG (Germany) | |||||||
| CooperSurgical Inc. (United States) | |||||||
| Pregna International Limited (India) | |||||||
| EUROGINE S.L. (Spain) | |||||||
| OCON Medical Ltd. (Israel) | |||||||
| Mona Lisa N.V. (Belgium) | |||||||
| SMB Corporation of India (India) | |||||||
| AbbVie Inc. (United States) | |||||||
| DKT International (United States) | |||||||
| Prosan International BV (Netherlands). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Society for Family Health | May-26 | Society for Family Health, in collaboration with the Oyo State Primary Health Care Board, conducted a dissemination meeting for the SHINE Research initiative focused on scaling hormonal intrauterine devices. The program evaluated implementation outcomes and strategies to expand access to hormonal IUDs in emerging markets. |
| Sebela Pharmaceuticals | Feb-25 | Sebela Pharmaceuticals received FDA approval for MIUDELLA, a contraceptive product indicated for pregnancy prevention in females of reproductive potential for up to three years. The approval expands the company’s reproductive health portfolio and strengthens its position in the long-acting contraceptive market. |
| CooperSurgical, Inc. | Sep-24 | CooperSurgical introduced a new single-hand inserter for Paragard, a hormone-free copper intrauterine device. The device launch improves ease of placement for clinicians and strengthens the usability and procedural efficiency of non-hormonal IUD insertion systems. |
| CooperSurgical Inc. | Sep-24 | CooperSurgical introduced a new single-hand inserter for its Paragard copper intrauterine device. The device is designed to improve procedural ease and placement efficiency in clinical settings, supporting enhanced usability for healthcare providers and reinforcing adoption of hormone-free IUD solutions in contraceptive care. |
| Medicines360 | Jan-24 | Medicines360 partnered with DKT WomanCare to expand access to AVIBELA, a hormonal intrauterine device with high contraceptive effectiveness. The collaboration focuses on improving distribution, affordability, and awareness of long-acting reversible contraceptive options across global markets. |
| Bayer | Nov-23 | Bayer entered a collaboration and licensing agreement with CrossBay Medical Inc. to develop a single-handed inserter integrated with its hormonal intrauterine system portfolio. The initiative aims to improve device usability for healthcare providers and enhance product differentiation in the IUD market. |
| Bayer AG | Nov-23 | Bayer and CrossBay Medical entered a licensing and development agreement to create a single-handed inserter for Bayer’s hormonal intrauterine system portfolio. The initiative enhances usability for healthcare providers and strengthens Bayer’s competitive positioning through improved device delivery and procedural efficiency in IUD administration. |
| Pregna International Limited | Jun-23 | Pregna International Limited secured a USD 16 million private equity investment from India Life Sciences Fund III managed by InvAscent. The funding is intended to support expansion and development of women’s reproductive health solutions, including intrauterine device offerings. |
| Bayer AG | Aug-22 | Bayer AG received FDA approval for a supplemental new drug application extending the use duration of its Mirena IUD to up to eight years. The approval strengthens its long-acting contraceptive portfolio and enhances product lifecycle positioning within the hormonal intrauterine device segment. |
| Medicines360 | Mar-22 | Medicines360, Population Services International, and Society for Family Health launched Avibela (levonorgestrel-releasing IUS) in Nigeria. The initiative expanded access to hormonal intrauterine contraception in West Africa through coordinated distribution and public health partnerships. |
| Medicines360 | Aug-21 | Medicines360, Population Services International, and Society for Family Health launched Avibela (levonorgestrel-releasing IUS) in Kenya. The rollout supported expansion of long-acting reversible contraceptive access in East Africa through multi-stakeholder public health collaboration. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Intrauterine Devices Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Contraceptive Intent | Pregnancy Prevention, Heavy Menstrual Bleeding Management, Other Therapeutic Use |
| Duration of Use | Short-Term Use, Medium-Term Use, Long-Term Use |
| Adoption Status | New Adoption, Replacement Use, Reinserted After Discontinuation |
Intrauterine Devices Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Contraceptive Access and Adoption Barriers |
|
| Long-Acting Contraception Access Strategy |
|
| Reproductive Health Policy and Market Access |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of intrauterine devices?
What is the forecasted size of the intrauterine devices industry?
How are government family planning programs driving adoption of intrauterine devices?
How is innovation in hormone-free IUDs influencing market demand?
Why do hormonal IUDs lead the intrauterine devices market?
Why are gynecology clinics the fastest-growing distribution channel for intrauterine devices?
Why does North America hold the largest share of the intrauterine devices market?
What factors are driving intrauterine devices market growth in Asia Pacific?
Which companies dominate the intrauterine devices landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization